Navigation Links
Researchers reveal most effective treatment for common kidney disorder
Date:1/9/2013

The results of a pioneering UK-wide clinical trial that compared treatments for patients with a common type of kidney disease has found one to be significantly more effective. The results of the study, published online in The Lancet today [9 Jan], will be recommended to clinicians worldwide as the most effective approach to treating the condition.

The Medical Research Council-funded study, led by researchers from the University of Bristol's Academic Renal Unit based in Southmead Hospital, compared three treatment approaches in a type of kidney disorder known as 'membranous nephropathy'.

The condition, which leads to changes and inflammation of the structures inside the kidney that help filter wastes and fluids, is usually managed with immunosuppressive drugs but has a high risk of causing kidney failure in patients. Previous studies of the disorder, which is costly to treat (kidney failure treatments cost $40 billion in the US in 2008), show that once kidney function starts to decline, continued deterioration can be expected.

The research team, led by Professor Peter Mathieson, Dean of the Faculty of Medicine and Dentistry, carried out a randomised controlled trial involving 108 patients with 20 per cent decline in renal function at 37 renal units across the UK. The patients were randomised to one of three treatment approaches and followed up by the team over three years.

The team evaluated results from 33 patients who were treated with prednisolone and chlorambucil, 37 patients with ciclosporin and 38 who were provided with supportive therapy alone.

They found that for patients with membranous nephropathy, six months' therapy with alternating monthly cycles of prednisolone and chlorambucil was the most effective option. This approach was shown to be the most effective in preventing further renal decline in patients with the benefits maintained over the three-year study period and thus the recommended treatment approach.

Professor Mathieson, the study's lead author and Dean of the Faculty of Medicine and Dentistry at the University, said: "Kidney failure is a devastating condition that is difficult and expensive to treat and our best strategies are to aim to prevent it wherever possible by more effective treatment of the underlying kidney problems. This clinical trial took a very long time to complete and I was helped by kidney specialists, research nurses and patients in Bristol and all over the UK. The results improve the evidence-base for our treatments in this form of kidney disease."


'/>"/>

Contact: Caroline Clancy
caroline.clancy@bristol.ac.uk
44-011-792-88086
University of Bristol
Source:Eurekalert

Related medicine news :

1. Researchers identify new target for common heart condition
2. USF and VA researchers find long-term consequences for those suffering traumatic brain injury
3. Pesticides and Parkinsons: UCLA researchers uncover further proof of a link
4. Mayo Clinic researchers find new molecule to target in pancreatic cancer treatment
5. Researchers zero in on cognitive difficulties associated with menopause
6. Common data determinants of recurrent cancer are broken, mislead researchers
7. Researchers identify an early predictor for glaucoma
8. PolyU Researchers Develop Novel Treatment for People with Hemiplegic Arms
9. A Serious Problem: Medical Malpractice Lawyers at Console & Hollawell React to Alarming Doctor Error Statistics from Johns Hopkins University Researchers
10. U of T Researchers uncover major source of evolutionary differences among species
11. MRIs reveal signs of brain injuries not seen in CT scans, UCSF/SFGH researchers report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , ... February 05, 2016 , ... The event is ... Day Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 ... owner of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this ...
(Date:2/5/2016)... ... 05, 2016 , ... Freed-Hardeman University President Joe A. Wiley ... joint enrollment and degree completion agreement. The agreement, which begins with the ... FHU|Dickson. , The agreement allows students to be jointly admitted to both ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
(Date:2/5/2016)... ... ... Boar’s Head Brand®, one of the nation’s leading providers of premium delicatessen ... stress out of your party preparation – follow these easy, yet delicious recipes with ... game. , “The key to hosting a successful game-day party is creating a flavorful ...
(Date:2/5/2016)... ... ... Stuart Bentkover, MD, FACS is thrilled to announce the arrival ... tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts to offer ... been approved by the Food and Drug Administration (FDA) as a safe and efficient ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016 Dehaier Medical ... or the "Company"), which develops, markets and sells ... China and international markets, ... which aims to concentrate the Company,s resources to ... respiratory business and to focus more on its ...
(Date:2/5/2016)... Site Profile: --> Site ... People, announced their latest primary healthcare case study where speech recognition ... and to save the practice money. Site Profile: ... Challenge: --> ,- Wirral CCG ,- VoicePower client since ... Wirral CCG ,- VoicePower client since 2013 Challenge: ...
(Date:2/4/2016)... Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... structural heart disease and critical care monitoring, announced today ... (ASR) agreement with Morgan Stanley & Co. LLC to ... is part of the Company,s previously authorized program to ... stock.  --> --> ...
Breaking Medicine Technology: